Caspofungin: Mode of action and therapeutic applications;La caspofungine: Du mécanisme d'action aux applications thérapeutiques

Revue de Medecine Interne

Volumn 27, Issue 1, 2006, Pages 32-39

  Datry, A ^a   Bart Delabesse, E ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Aspergillosis; Candidiasis; Caspofungin; Empirical therapy; (1,3) D glucan

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; HEXAPEPTIDE; PLASMA PROTEIN; PNEUMOCANDIN DERIVATIVE; TRIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TOLERABILITY; FEVER; HUMAN; INJECTION SITE REACTION; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; REVIEW; VOMITING;

EID: 29944445883     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2005.05.012     Document Type: Short Survey

References (43)

1. E. Anaissie Opportunistic mycoses in the immunocompromised host: experienced at a cancer center and review Clin. Infect. Dis. 14 1992 S43 S53
2. S.H. Khoo, and D.W. Dening Invasive aspergillosis in patients with AIDS Clin. Infect. Dis. 19 1994 S41 S48
3. C. Beck-Sagú, and W.R. Jarvis Secular trends in the epidemiology of nosocomial fungal infections in the United States J. Infect. Dis. 167 1993 1247 1251 (National Nosocomial Infections Surveillance System)
4. W.R. Jarvis, J.R. Edwards, D.H. Culver, J.M. Hughes, T. Horan, and T.G. Emon Nosocomial infection rates in adult and pediatric care units in the United States Am. J. Med. 91 1991 1855 1915 (National Nosocomial Infections Surveillance System)
5. M.B. Edmond, S.E. Wallace, D.K. McClish, M.A. Pfaller, R.N. Jones, and R.P. Wenzel Nosocomial bloodstreams infections in United States hospitals: a three years analysis Clin. Infect. Dis. 29 1999 239 244
6. J.R. Wingard, M.H. White, E. Anaissie, J. Raffalli, J. Goodman, and A. Arrieta A randomised, double blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia Clin. Infect. Dis. 31 2000 1155 1163
7. J.H. Rex, M.G. Rinaldi, and M.A. Pfaller Resistance of Candida species to fluconazole Antimicrob. Agents Chemother. 39 1995 1 8
8. C.A. Kauffman Zygomycosis: reemergence of an old pathogen Clin. Infect. Dis. 39 2004 588 590
9. G.T. Siwek, K.J. Dogson, M. de Magalhaes-Silverman, L.A. Bartelft, S.B. Kilborn, and P.L. Hoth Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis Clin. Infect. Dis. 39 2004 584 587
10. A.T. Hoang Caspofungin acetate: an antifungal agent Am. J. Health Syst. Pharm. 58 2001 1206 1214
11. A. Datry, M. Thellier, O. Alfa Cisse, and M. Danis Utilisation des antifongiques dans le traitement des candidoses syst́miques:: antifongigramme, point sur les ŕsistances, donńes pharmacologiques Ann. Fr. Anesth. Reanim. 20 2001 389 393
12. Caspofungin. L743, 872, MK-0991, MK-991 Drugs R D. 1 1999 165 167 (No author list)
13. D.W. Denning Echinocandins and pneumocandins: a new antifungal class with a novel mode of action J. Microb. Chemother. 40 1997 611 614
14. K. Bartizal, C.J. Gill, C.K. Abruzzo, A.M. Flattery, L. Kong, and P.M. Scott In vitro preclinical evaluation of studies with the echinocandin antifungal MK-0991 (L743, 872) Antimicrob. Agents Chemother. 41 1997 2326 2332
15. th ICAAC; Toronto 2000
16. A. Espinel-Ingroff Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts J. Clin. Microbiol. 36 1998 2950 2956
17. th ICAAC; Toronto 2000
18. P.W. Nelson, M. Lozano-Chiu, and J.H. Rex In vitro growth-inhibitory activity of pneumocandins L733, 560 and L743, 872 against putatively amphotericin B and fluconazole-resistant Candida isolates: influence of assay conditions J. Med. Vet. Mycol. 35 1997 285 287
19. G.K. Abruzzo, C.J. Gill, A.M. Flattery, L. Kong, C. Leighton, and J.G. Smith Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice Antimicrob. Agents Chemother. 44 2000 2310 2318
20. th ICAAC; News Orleans 1996
21. G.K. Abruzzo, A.M. Flattery, C.J. Gill, L. Kong, J.G. Smith, and V.B. Pikounis Evaluation of the echinocandin antifungal MK-0991 (L-743, 872): efficacies of mouses models of disseminated aspergillosis, candidiasis and cryptococcosis Antimicrob. Agents Chemother. 41 1997 2333 2338
22. J.R. Graybill, L.K. Najvar, E.M. Montalbo, F.J. Barchiesi, M.F. Luther, and M.G. Rinaldi Treatment of histoplasmosis with MK 0991 (L-743, 872) Antimicrob. Agents Chemother. 42 1998 151 153
23. M.A. Powles, P. Liberator, J. Anderson, Y. Karkhanis, J.F. Dropinski, and F.A. Bouffard Efficacy of MK0991 (L743,872), a semisynthetic pneumocandin in murin models of Pneumocystis carinii Antimicrob. Agents Chemother 42 1998 1985 1989
24. B. Spellberg, Y. Fu, J.E. Edwards Jr., and A.S. Ibrahim Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice Antimicrob. Agents Chemother. 49 2005 830 832
25. J.A. Stone, S.D. Holland, P.J. Wickersman, A. Sterrett, M. Schwartz, and C. Bonfiglio Single and multiple dose pharmacokinetics of Caspofungin in healthy men Antimicrob. Agents Chemother. 46 2002 739 745
26. R. Hajdu, R. Thompson, J.G. Sundelof, B.A. Pelak, F.A. Bouffard, and J.F. Dropinski Preliminary animal pharmacokinetics of the parenteral antifungal agent MK 0991 (L-743,872) Antimicrob. Agents Chemother. 41 1997 2339 2344
27. Merck and Co Cancidas (caspofungin acetate) prescribing information, Merck & Co. Available from URL: http:://www.merck.com (Accessed 2001 Mar 16).
28. S.K. Balani, X. Xu, B.H. Arison, M.V. Silva, A. Gries, and F.A. Deluna Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine Drug Metab. Dispos. 28 2000 1274 1278
29. G.M. Keating, and B. Jarvis Caspofungin Drugs 61 2001 1121 1129
30. nd ICAAC; San Diego 2002
31. J. Garbino Caspofungin- a new therapeutic option for oropharyngeal candidiasis Clin. Microbiol. Infect. 10 2004 187 189
32. A. Villanueva, E.G. Arathoon, L.M. Gotuzzo-Noriega, K.A. Kartsonis, and R. Lupinacci A randomized double-blind study of caspofungin versus amphotericinB for the treatment of esophageal candidiasis Clin. Infect. Dis. 33 2001 1529 1535
33. E.G. Arathoon, E. Gotuzzo, L.M. Noriega, R.S. Berman, M.J. DiNubile, and C.A. Sable Randomized, double blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis Antimicrob. Agents Chemother. 46 2002 451 457
34. A. Villanueva, E. Gotuzzo, E.G. Arathoon, L.M. Noriega, K.A. Kartsonis, and R. Lupinacci A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis Am. J. Med. 113 2002 294 299
35. J. Mora-Duarte, R. Betts, C. Rotstein, A. Lopes Colombo, L. Thompson-Moya, and J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N. Engl. J. Med. 347 2002 2020 2029
36. J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, and F.B. Petersen Efficacy and safety of caspofungin for treatment of invasive aspergillosis for patients refractory or intolerant of conventional antifungal therapy Clin. Infect. Dis. 39 2004 1563 1571
37. T.J. Walsh, H. Teppler, G.R. Donowitz, M.D. Johan, M.D. Maertens, and L.R. Baden Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N. Engl. J. Med. 351 2004 1391 1402
38. E. Dannaoui, O. Lortholary, and F. Dromer In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus Antimicrob. Agents Chemother. 48 2004 970 978
39. th ICAAC; Washington 2004
40. C.A. Sable, B.Y. Nguyen, J. Cholakewitz, and M.J. DiNubile Safety and tolerability of acetate (CA) in the treatment of fungal infections Transpl. Infect. Dis. 4 2002 25 30
41. J. Lynch, and A. Wong-Beringer Caspofungin: a potentiel cause of reversible thrombocytopenia Pharmacotherapy 24 2004 148 151
42. D.A. Stevens, M. Espiritu, and R. Parmar Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations Antimicrob. Agents Chemother. 48 2004 3407 3411
43. K.A. Maar, R. Hachem, G. Papanicolaou, J. Somani, J.M. Arduino, and C.J. Lipka Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A Transpl. Infect. Dis. 6 2004 110 116